PREVACID IV Drug Patent Profile

When do Prevacid Iv patents expire, and when can generic versions of Prevacid Iv launch?

Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA.

The generic ingredient in PREVACID IV is lansoprazole. There are fifty-six drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the lansoprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prevacid Iv

A generic version of PREVACID IV was approved as lansoprazole by MYLAN PHARMS INC on November 10^th, 2009.

Summary for PREVACID IV

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	162
Clinical Trials:	42
Patent Applications:	3,976
DailyMed Link:	PREVACID IV at DailyMed

Recent Clinical Trials for PREVACID IV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Research & Development, LLC	Phase 1
McGill University Health Center	Phase 4
McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4

See all PREVACID IV clinical trials

US Patents and Regulatory Information for PREVACID IV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004		DISCN	Yes	No

Expired US Patents for PREVACID IV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004	4,628,098*PED
Takeda Pharms Na	PREVACID IV	lansoprazole	INJECTABLE;INTRAVENOUS	021566-001	May 27, 2004	7,396,841*PED

International Patents for PREVACID IV

See the table below for patents covering PREVACID IV around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	19975017
Hungary	T39444
Spain	546152
Norway	163131
Netherlands	930109

Supplementary Protection Certificates for PREVACID IV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
1129088	2014/008	Ireland		PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919

PREVACID IV Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Proton Pump Inhibitors (PPIs) - A Focus on Prevacid (Lansoprazole)

Introduction to Proton Pump Inhibitors (PPIs)

Proton Pump Inhibitors (PPIs) are a class of medications widely used to treat various gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease, and NSAID-induced gastric ulcers. Prevacid, known generically as lansoprazole, is one of the prominent PPIs in the market.

Global PPI Market Overview

The global PPI market has been experiencing steady growth, driven by several key factors. The market size is projected to grow from $3.3 billion in 2023 to $3.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. By 2028, the market is expected to reach $4.12 billion, with a CAGR of 4.6%[1].

Drivers of the PPI Market

Several factors are driving the growth of the PPI market:

• Increasing Prevalence of Gastrointestinal Disorders: The rising incidence of GERD, peptic ulcer disease, and other gastrointestinal conditions is a significant driver. For instance, over 40% of Americans have stopped engaging in daily activities due to severe gastrointestinal symptoms[1].
• Aging Population and Changing Lifestyles: The aging population and changes in dietary habits contribute to the increased demand for PPIs.
• Emerging Markets and Patient Education: Adoption in emerging markets and patient education initiatives are also boosting the market[1].

Lansoprazole (Prevacid) Market Specifics

Lansoprazole, marketed under the brand name Prevacid, is a key player in the PPI market.

Market Size and Growth

The lansoprazole market was valued at $1.89 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030, reaching nearly $2.81 billion by 2030[4].

Product Types and Administration Routes

Lansoprazole is available in various forms, including capsules, orally disintegrating (OD) tablets, and botulinum toxin injections. The oral route of administration is expected to hold the largest market share due to patient preference for capsule formulations and the low cost of oral capsules[4].

Regional Insights

The North American region is expected to dominate the lansoprazole market, driven by a high prevalence of GERD in the United States. According to the World Gastroenterology Organisation, the prevalence of GERD in North America ranges from 13.8% to 25.8%, significantly higher than in other regions[4].

Trends and Strategies in the PPI Market

Several trends are shaping the future of the PPI market:

Integration with Digital Health Solutions

The integration of PPIs with digital health solutions is becoming more prevalent, enhancing patient compliance and monitoring[1].

Global Market Expansion

Companies are expanding their reach into emerging markets, which is expected to drive growth in the coming years[1].

Focus on Gastrointestinal Health Education

Patient education initiatives are crucial in increasing awareness and diagnosis of gastrointestinal disorders, thereby driving the demand for PPIs[1].

Regulatory Updates and Safety Measures

Regulatory updates and safety measures are important factors, as they impact the approval and use of PPIs. For example, the higher effectiveness of IV PPI therapy may not offset its increased costs compared to oral PPI therapy in certain cases[5].

Challenges and Restraints

Despite the growth, the PPI market faces several challenges:

• Chronic Side Effects: Long-term use of PPIs can lead to chronic side effects, which is a major factor hampering market growth[3].
• Alternative Medications: The availability of alternative medication classes such as H2 blockers and antacids can reduce the demand for PPIs[4].

Financial Performance and Projections

The financial performance of the PPI market, including lansoprazole, is robust. Here are some key financial projections:

• Revenue Growth: The lansoprazole market is expected to grow significantly, reaching $2.81 billion by 2030[4].
• Market Share: The North American region is expected to hold a significant market share due to high demand and prevalence of GERD[4].

Industry Expert Insights

Industry experts emphasize the importance of innovation and patient education. For instance, Perrigo, a major player in the self-care market, has highlighted the need for constant innovation to meet consumer demands for both treatment and prevention products[2].

Key Statistics

• Market Size: The global PPI market is expected to reach $4.12 billion by 2028[1].
• CAGR: The lansoprazole market is expected to grow at a CAGR of 5.8% from 2024 to 2030[4].
• Prevalence of GERD: The prevalence of GERD in North America ranges from 13.8% to 25.8%[4].

Conclusion

The market for proton pump inhibitors, including lansoprazole (Prevacid), is poised for steady growth driven by increasing prevalence of gastrointestinal disorders, emerging market adoption, and patient education initiatives. Despite challenges such as chronic side effects and alternative medications, the market is expected to expand significantly in the coming years.

Key Takeaways

• The global PPI market is projected to grow to $4.12 billion by 2028.
• Lansoprazole is expected to grow at a CAGR of 5.8% from 2024 to 2030.
• The North American region will dominate the lansoprazole market due to high GERD prevalence.
• Integration with digital health solutions and patient education are key trends.
• Chronic side effects and alternative medications are significant restraints.

Frequently Asked Questions (FAQs)

What are the primary drivers of the PPI market?

The primary drivers include the increasing prevalence of gastrointestinal disorders, an aging population, changing lifestyles, and emerging market adoption[1].

How is the lansoprazole market expected to grow?

The lansoprazole market is expected to grow at a CAGR of 5.8% from 2024 to 2030, reaching nearly $2.81 billion by 2030[4].

What are the major trends in the PPI market?

Major trends include integration with digital health solutions, global market expansion, focus on gastrointestinal health education, and regulatory updates and safety measures[1].

What are the challenges faced by the PPI market?

Challenges include chronic side effects associated with long-term use and the availability of alternative medication classes such as H2 blockers and antacids[3][4].

Which region is expected to dominate the lansoprazole market?

The North American region is expected to dominate the lansoprazole market due to a high prevalence of GERD in the United States[4].

Cited Sources:

1. The Business Research Company - Global Proton Pump Inhibitors Market Report 2024
2. Perrigo Company plc - Annual Report 2021
3. Managed Healthcare Executive - Peptic Ulcer Disease Drug Pipeline: What You Need to Know
4. Maximize Market Research - Lansoprazole Market: Global Industry Analysis and Forecast
5. Clinical Gastroenterology and Hepatology - The Cost-Effectiveness and Budget Impact of Intravenous Versus Oral Proton Pump Inhibitor Therapy in Ulcer Hemorrhage